Hematology News‘Outstanding data’: Mosunetuzumab in r/r follicular lymphomaDecember 11, 2021B Cell LymphomaFollicular Lymphoma
Hematology News‘Remarkable’ results with CAR T cells could make chemo obsoleteDecember 11, 2021B Cell Lymphoma
Hematology NewsIn some lymphomas, ibrutinib yields “almost unheard-of” survival ratesDecember 8, 2021DLBCLB Cell Lymphoma
Hematology NewsEasing access to DLBCL treatments: Patient study reveals racial differencesNovember 17, 2021DLBCLB Cell Lymphoma
Hematology NewsNew trials in lymphoma and MM: Could your patient benefit?November 10, 2021DLBCLMantle Cell LymphomaB Cell Lymphoma
Hematology NewsOn improving DLBCL outcomes, single-agent regimens fall shortOctober 20, 2021DLBCLB Cell Lymphoma
Hematology NewsBTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignanciesOctober 15, 2021CLLB Cell Lymphoma
Hematology NewsFDA grants zanubrutinib an accelerated approval in marginal zone lymphomaSeptember 16, 2021B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsCan reversing T-cell exhaustion benefit in B-cell lymphoma relapse?September 15, 2021B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsFDA approves zanubrutinib in Waldenström’s macroglobulinemiaSeptember 7, 2021B Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsHematologic cancer increases risk of delivery complicationsJuly 22, 2021Gynecologic CancerB Cell Lymphoma
Hematology NewsReal-world CAR T outcomes for DLBCL mimic clinical trialsJune 28, 2021DLBCLB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsExperimental antibody-drug conjugate shown active against r/r DLBCLJune 15, 2021B Cell LymphomaDLBCLLymphoma & Plasma Cell Disorders
Hematology NewsChoosing the right R-CHOP dosage for elderly patients with DLBCLJune 8, 2021DLBCLB Cell LymphomaLymphoma & Plasma Cell Disorders
Hematology NewsHigh-dose methotrexate of no CNS benefit for patients with high-risk DLBCLMay 18, 2021B Cell LymphomaDLBCLLymphoma & Plasma Cell Disorders
